OVID THERAPEUTICS INC. (NASDAQ:OVID) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item5.03. Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
Amendment and Restatement of Certificate of
Incorporation
On May10, 2017, Ovid Therapeutics Inc. (the
Company) filed an amended and restated
certificate of incorporation (the Restated
Certificate) with the Secretary of State of the
State of Delaware, in connection with the closing of the Companys
initial public offering of shares of its common stock (
IPO). The Companys board of directors
and stockholders previously approved the Restated Certificate on
April12, 2017 and April24, 2017, respectively, which went
effective immediately after to the closing of its IPO.
The foregoing description of the Restated Certificate is
qualified in its entirety by reference to the full text of the
Restated Certificate, which is filed as Exhibit3.1 hereto, and is
incorporated herein by reference.
Amendment and Restatement of Bylaws
Effective as of May10, 2017, the Company adopted amended and
restated bylaws (the Restated Bylaws)
in connection with the closing of its IPO. The Companys board of
directors and stockholders previously approved the Restated
Bylaws on April12, 2017 and April24, 2017, respectively, which
went effective immediately prior to the closing of its initial
public offering.
The foregoing description of the Restated Bylaws is qualified in
its entirety by reference to the full text of the Restated
Bylaws, which is filed as Exhibit3.2 hereto, and is incorporated
herein by reference.
Item9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit No. |
Description |
|
| 3.1 |
Amended and Restated Certificate of Incorporation of the Company. |
|
| 3.2 | Amended and Restated Bylaws of the Company. |
About OVID THERAPEUTICS INC. (NASDAQ:OVID)
Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. OVID THERAPEUTICS INC. (NASDAQ:OVID) Recent Trading Information
OVID THERAPEUTICS INC. (NASDAQ:OVID) closed its last trading session up +0.39 at 13.73 with 44,887 shares trading hands.
